Pilot study of weekly chemo-hormono-immunotherapy including Cisplatin (C), Epirubicin (E), Medroxyprogesterone Acetate (MPA) + rhuIL-2, followed by Docetaxel (T) plus Cisplatin in patients with stage IIIB-IV non-small-cell lung cancer (NSCLC)